YaoGeJu

Public drug landscapesDrug landscape

Fluticasone Propionate Cream

As of 13 November 2026, for Fluticasone Propionate Cream, 12 applications are listed as under review at China's CDE; 2 companies have filed new generic applications in 2026; the chemical-drug catalogue lists 0 holders.

Companies, stages and changes, with each record available on this page.

Last 90 days: Accepted: 2 applications

Current coverage may be incomplete

Follow for free
Complete CDE snapshot
2026/11/13 06:42
Matching scope
Same generic name; dosage forms and combinations kept separate

US Orange Book listing

The brand names come from the US FDA Orange Book and describe US listing records for this active ingredient. They do not indicate that products under these brand names are approved or sold in China, or that Chinese applicants are affiliated with US holders.

Orange Book source export date: 2026/11/06. Version: 2026-11-06.

Showing 5 of 11 distinct brand names.

A brand with different source forms or statuses can appear on multiple rows and in both groups. Distinct brand names are counted once globally, with a limit of five.

Verified official English dosage form: Cream. Listings are grouped by the source dosage form and route; records without a clear correspondence are listed in the other group. Grouping does not establish product equivalence.

Same dosage form

No listings in this group among the displayed brand names.

Other dosage forms of the same ingredient

Brand nameApplicant (source text)Application numberDosage form (source text)Route (source text)Marketing status (source text)Approval date
FLOVENT DISKUS 100 GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE NDA 020833 · Product no. 002 POWDER INHALATION HUMAN PRESCRIPTION DRUG 2000/09/29
FLOVENT DISKUS 250 GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE NDA 020833 · Product no. 003 POWDER INHALATION HUMAN PRESCRIPTION DRUG 2000/09/29
FLOVENT DISKUS 50 GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE NDA 020833 · Product no. 001 POWDER INHALATION HUMAN PRESCRIPTION DRUG 2000/09/29
FLOVENT HFA GLAXO GROUP LTD DBA GLAXOSMITHKLINE NDA 021433 · Product no. 001, 002, 003 AEROSOL, METERED INHALATION HUMAN PRESCRIPTION DRUG 2004/05/14
FLONASE ALLERGY RELIEF HALEON US HOLDINGS LLC NDA 205434 · Product no. 001 SPRAY, METERED NASAL HUMAN OTC DRUG 2014/07/23

Same-form/route listings come first, followed by other forms/routes. Within each group, source prescription/OTC listings precede discontinued listings; unknown statuses are last. Each status bucket is ordered by earliest approval date, ascending: pre-1982 records first, missing dates last; ties by brand name, application number and product number. The first five distinct brands in this order are selected globally. All retained source facts for those brands are shown in their own groups; a brand spanning both groups counts once.

Ingredient cross-list details ↗

Which companies are listed, and at what stages?

Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.

Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.

Chemical-drug catalogue

Loaded records: 0 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 0 in the new chemical-registration-classification generic category. Category counts may overlap.

Marketing authorization holderManufacturerApproval numberApprovedStrength / specificationCatalogue category (source text)View source
No matching records were found in the currently loaded source data; coverage dates are listed below.

Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.

NHSA drug codes

Loaded records: 12 distinct approval numbers and 11 companies.

Company / applicantApproval numberStrength / specificationNHSA classNHSA drug codeView source
Chongqing Huapont Pharmaceutical Co., Ltd.国药准字H202545890.05%(15g:7.5mg)Category BXD07ACF095F002010101003NHSA
Hubei Heng An Fu Lin Pharma Co., Ltd. romanized国药准字H201035010.05%Category BXD07ACF095F002010101808NHSA
Wuhan Nuo An Pharma Co., Ltd. romanized国药准字H201733460.05%(15g:7.5mg)Category BXD07ACF095F002010101955NHSA
Hebei Xin Zhang Yao Co., Ltd. romanized国药准字H202643440.05%(15g:7.5mg)Category BXD07ACF095F002010102673NHSA
Zhejiang San Sheng Man Di Pharma Co., Ltd. romanized国药准字H201732700.05%Category BXD07ACF095F002010104726NHSA
Zhejiang Xian Ju Pharmaceutical Co., Ltd. romanized国药准字H201033370.05%Category BXD07ACF095F002010104735NHSA
Ao Mei Pharmaceutical Factory romanized国药准字HC201500210.05%[(1)5g:2.5mg;(2)10g:5mg;(3)15g:7.5mgCategory BXD07ACF095F002010179136NHSA
Glaxo Wellcome UK LimitedH2013043115g:7.5mg(0.05%)Category BXD07ACF095F002010179536NHSA
Fu Yuan Pharma Co., Ltd. romanized国药准字H202444390.05%(15g∶7.5mg)Category BXD07ACF095F002010180651NHSA
Jiangsu Ziyond Pharmaceutical Co., Ltd.国药准字H202538140.05%(15g:7.5mg)Category BXD07ACF095F002010181475NHSA
Hubei Heng An Fu Lin Pharma Co., Ltd. romanized国药准字H201035010.05%Category BXD07ACF095F002020101808NHSA
Wuhan Nuo An Pharma Co., Ltd. romanized国药准字H201733460.05%(15g:7.5mg)Category BXD07ACF095F002020101955NHSA
Zhejiang Xian Ju Pharmaceutical Co., Ltd. romanized国药准字H201033370.05%Category BXD07ACF095F002020104735NHSA
Ao Mei Pharmaceutical Factory Co., Ltd. romanized国药准字HC201500220.05%[(1)5g:2.5mg;(2)10g:5mg;(3)15g:7.5mg;(4)20g:Category BXD07ACF095F002020179136NHSA
Fu Yuan Pharma Co., Ltd. romanized国药准字H202582130.05%(20g∶10mg)Category BXD07ACF095F002020180651NHSA
Hubei Heng An Fu Lin Pharma Co., Ltd. romanized国药准字H201035010.05%Category BXD07ACF095F002030101808NHSA
Wuhan Nuo An Pharma Co., Ltd. romanized国药准字H201733460.05%(15g:7.5mg)Category BXD07ACF095F002030101955NHSA
Zhejiang Xian Ju Pharmaceutical Co., Ltd. romanized国药准字H201033370.05%Category BXD07ACF095F002030104735NHSA
Ao Mei Pharmaceutical Factory romanized国药准字HC201500210.05%[(1)5g:2.5mg;(2)10g:5mg;(3)15g:7.5mgCategory BXD07ACF095F002030179136NHSA
Wuhan Nuo An Pharma Co., Ltd. romanized国药准字H201733460.05%(15g:7.5mg)Category BXD07ACF095F002030201955NHSA
Hubei Heng An Fu Lin Pharma Co., Ltd. romanized国药准字H201035010.05%Category BXD07ACF095F002040101808NHSA
Wuhan Nuo An Pharma Co., Ltd. romanized国药准字H201733460.05%(15g:7.5mg)Category BXD07ACF095F002040101955NHSA
Ao Mei Pharmaceutical Factory Co., Ltd. romanized国药准字HC201500220.05%[(1)5g:2.5mg;(2)10g:5mg;(3)15g:7.5mg;(4)20g:Category BXD07ACF095F002040179136NHSA
Wuhan Nuo An Pharma Co., Ltd. romanized国药准字H201733460.05%(15g:7.5mg)Category BXD07ACF095F002050101955NHSA
Ao Mei Pharmaceutical Factory Co., Ltd. romanized国药准字HC201500220.05%[(1)5g:2.5mg;(2)10g:5mg;(3)15g:7.5mg;(4)20g:Category BXD07ACF095F002050179136NHSA
Wuhan Nuo An Pharma Co., Ltd. romanized国药准字H201733460.05%(15g:7.5mg)Category BXD07ACF095F002060101955NHSA

Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.

Current under-review applications

Loaded records: 12 filings and 10 distinct first applicants.

Supplement 2 · Generic 10

Current under-review applications
Company / applicantAcceptance numberApplication typeAcceptedStrength / specificationView source
Fu Yuan Pharma Co., Ltd. romanizedCYHB2601871Supplement2026/10/13Not stated by sourceCDE
Chongqing Huapont Pharmaceutical Co., Ltd.CYHB2601651Supplement2026/08/28Not stated by sourceCDE
Zhejiang Gao Zhi Pharmaceuticals Technology Co., Ltd. romanized; Zhejiang Sai Mo Pharmaceutical Co., Ltd. romanizedCYHS2600577Generic2026/02/28Not stated by sourceCDE
Guangdong Ren Xiang Pharma Co., Ltd. romanized; Zhejiang Sai Mo Pharmaceutical Co., Ltd. romanizedCYHS2600360Generic2026/02/04Not stated by sourceCDE
Guangdong Ren Xiang Pharma Co., Ltd. romanized; Zhejiang Sai Mo Pharmaceutical Co., Ltd. romanizedCYHS2600359Generic2026/02/04Not stated by sourceCDE
Zhejiang AngLiKang Pharmaceutical CO.,LTD.CYHS2504507Generic2025/12/31Not stated by sourceCDE
Zhejiang Bai Dai Pharmaceuticals Technology Co., Ltd. romanized; Zhejiang Sai Mo Pharmaceutical Co., Ltd. romanizedCYHS2504470Generic2025/12/30Not stated by sourceCDE
Zhejiang Bai Dai Pharmaceuticals Technology Co., Ltd. romanized; Zhejiang Sai Mo Pharmaceutical Co., Ltd. romanizedCYHS2504469Generic2025/12/30Not stated by sourceCDE
Hangzhou Ling Ye Pharmaceuticals Technology Co., Ltd. romanizedCYHS2503797Generic2025/10/28Not stated by sourceCDE
Hunan Ming Rui Pharmaceutical Co., Ltd. romanizedCYHS2503783Generic2025/10/24Not stated by sourceCDE
Zhejiang Hua Hai Pharmaceutical Technology Co., Ltd. romanizedCYHS2503638Generic2025/10/11Not stated by sourceCDE
Zhejiang Zhi Xin Pharmaceuticals Technology Co., Ltd. romanized; Zhejiang Xian Ju Pharmaceutical Co., Ltd. romanizedCYHS2501501Generic2025/04/19Not stated by sourceCDE
New generic filings in 2026

Loaded records: 3 filings and 2 distinct first applicants.

New generic filings in 2026
Company / applicantAcceptance numberApplication typeAcceptedStrength / specificationView source
Zhejiang Gao Zhi Pharmaceuticals Technology Co., Ltd. romanized; Zhejiang Sai Mo Pharmaceutical Co., Ltd. romanizedCYHS2600577Generic2026/02/28Not stated by sourceCDE
Guangdong Ren Xiang Pharma Co., Ltd. romanized; Zhejiang Sai Mo Pharmaceutical Co., Ltd. romanizedCYHS2600360Generic2026/02/04Not stated by sourceCDE
Guangdong Ren Xiang Pharma Co., Ltd. romanized; Zhejiang Sai Mo Pharmaceutical Co., Ltd. romanizedCYHS2600359Generic2026/02/04Not stated by sourceCDE
API registrations

Non-component matches: 18 companies with A status and 7 I-status records. Component matches are listed separately and excluded from these counts.

NameCompany / applicantRegistration numberStatusName matchSource update dateView source
丙酸氟替卡松 · No verified English nameGlaxo Operations UK LimitedY20260000761IExact ingredient2026/09/02CDE
丙酸氟替卡松 · No verified English nameCuria Spain S.A.U.Y20240000551IExact ingredient2024/07/17CDE
丙酸氟替卡松 · No verified English nameGlaxo Wellcome Manufacturing Pte LtdY20230001274AExact ingredient2025/12/05CDE
丙酸氟替卡松 · No verified English nameINDUSTRIALE CHIMICA S.R.L.Y20230000326AExact ingredient2026/03/07CDE
丙酸氟替卡松 · No verified English nameBo Ze Ge Lin (Shandong) Pharma Co., Ltd. romanizedY20230000446AExact ingredient2025/04/16CDE
丙酸氟替卡松 · No verified English nameCIPLA LIMITEDY20230000328AExact ingredient2025/12/13CDE
丙酸氟替卡松 · No verified English nameVAMSI LABS LTD.Y20230000256AExact ingredient2025/09/22CDE
丙酸氟替卡松 · No verified English nameHenan Li Hua Pharmaceutical Co., Ltd. romanizedY20200001241AExact ingredient2025/08/01CDE
丙酸氟替卡松 · No verified English nameShandong Si Rui Pharma Co., Ltd. romanizedY20200000871AExact ingredient2024/05/30CDE
丙酸氟替卡松 · No verified English nameGlaxo Wellcome Manufacturing Pte LtdY20200000383AExact ingredient2023/01/04CDE
丙酸氟替卡松 · No verified English nameSANOFI CHIMIEY20190021448IExact ingredient2020/06/30CDE
丙酸氟替卡松 · No verified English nameSichuan Ren An Pharma Co., Ltd. romanizedY20200000487AExact ingredient2026/06/08CDE
丙酸氟替卡松 · No verified English nameHovione FarmaCiencia SAY20200000007IExact ingredient2023/09/12CDE
丙酸氟替卡松 · No verified English nameJin Yao Pharma Co., Ltd. romanizedY20190008858AExact ingredient2026/03/21CDE
丙酸氟替卡松 · No verified English nameLian Yun Gang Run Zhong Pharmaceutical Co., Ltd. romanizedY20190007593AExact ingredient2024/06/06CDE
丙酸氟替卡松 · No verified English nameAo Rui Te Pharma Co., Ltd. romanizedY20190007020AExact ingredient2022/10/28CDE
丙酸氟替卡松 · No verified English nameAarti Industries LimitedY20180001420IExact ingredient2022/02/14CDE
丙酸氟替卡松 · No verified English nameCipla LtdY20180000678IExact ingredient2023/03/24CDE
丙酸氟替卡松 · No verified English nameSterling S.p.A.Y20180000012AExact ingredient2026/08/30CDE
丙酸氟替卡松 · No verified English nameGlaxo Operations UK Limited trading as Glaxo Wellcome OperationsY20170002132IExact ingredient—CDE
丙酸氟替卡松 · No verified English nameHubei Heng An Fu Lin Pharma Co., Ltd. romanizedY20170001421AExact ingredient2026/07/14CDE
丙酸氟替卡松 · No verified English nameShandong Rui Shun Pharma Co., Ltd. romanizedY20170001404AExact ingredient2026/05/20CDE
丙酸氟替卡松 · No verified English nameWuhan Nuo An Pharma Co., Ltd. romanizedY20170000801AExact ingredient2026/02/07CDE
丙酸氟替卡松 · No verified English nameHubei Ge Dian Ren Fu Pharma Co., Ltd. romanizedY20170000546AExact ingredient2023/05/23CDE
丙酸氟替卡松 · No verified English nameChongqing Sheng Kai Pharmaceutical Co., Ltd. romanizedY20170000171AExact ingredient2025/04/17CDE
丙酸氟替卡松 · No verified English nameZhejiang Xian Ju Pharmaceutical Co., Ltd. romanizedY20170000025AExact ingredient2024/08/07CDE

A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.

What changed recently?

Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.

Trial registration does not mean an application will follow.

This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.

NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/13 06:39. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.

This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.

  1. 2026/10/13Accepted

    Fu Yuan Pharma Co., Ltd. romanized

    CYHB2601871

    Fact date: 2026/10/13 · Site observation date: 2026/10/22

    View source ↗
  2. 2026/08/28Accepted

    Chongqing Huapont Pharmaceutical Co., Ltd.

    CYHB2601651

    Fact date: 2026/08/28 · Site observation date: 2026/10/22

    View source ↗

How current is each source?

CDE acceptances and review
Last successful update: 2026/11/13 06:42
Chemical-drug catalogue
Last successful update: 2026/11/13 06:39

Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.

Full API register
Last successful update: 2026/11/13 06:41
NHSA drug codes
Last successful update: 2026/11/05 06:45

The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.

NMPA drug delivery notices
Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete

First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.

Drug Clinical Trial Registry and Information Disclosure Platform
Last successful update: 2026/11/13 08:09 · Current coverage may be incomplete

Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.

This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.

Public-product searches scanned: 7/30; discovered pending details: 13. Record counts in unscanned portions remain unknown.

Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.

Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

Free follow

Follow changes to Fluticasone Propionate Cream

Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.

Confirmation links expire in 7 days. No digest is sent before confirmation; existing follows are not duplicated.

Sign in to choose products